Comparative Pharmacology
Head-to-head clinical analysis: EMPAGLIFLOZIN versus SEGLUROMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMPAGLIFLOZIN versus SEGLUROMET.
EMPAGLIFLOZIN vs SEGLUROMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor; reduces renal glucose reabsorption, increasing urinary glucose excretion.
SEGLUROMET is a fixed-dose combination of ertugliflozin and metformin. Ertugliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Metformin decreases hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity.
10 mg orally once daily, with or without food; may increase to 25 mg once daily if eGFR ≥60 mL/min/1.73 m² and additional glycemic control needed.
Initial: 2.5 mg ertugliflozin/1000 mg metformin twice daily. Titrate based on efficacy and tolerability. Maximum: 5 mg ertugliflozin/2000 mg metformin twice daily.
None Documented
None Documented
Clinical Note
moderateEmpagliflozin + Gatifloxacin
"Empagliflozin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateEmpagliflozin + Rosoxacin
"Empagliflozin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateEmpagliflozin + Levofloxacin
"Empagliflozin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateEmpagliflozin + Trovafloxacin
"Empagliflozin may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life is approximately 12.4 hours (range 10-18 h) in patients with T2DM; supports once-daily dosing.
Ertugliflozin: terminal half-life ~16.6 hours (range 10-20 h), supporting once daily dosing. Metformin: terminal half-life ~6.2 hours (range 4-8.7 h) in patients with normal renal function; prolonged in renal impairment.
Renal (54% as unchanged drug) and fecal (41% as unchanged drug or metabolites); biliary excretion is minimal.
Segluromet (ertugliflozin and metformin) is primarily excreted via renal (ertugliflozin: ~40.9% unchanged in urine; metformin: ~90% unchanged in urine) and fecal/biliary routes (ertugliflozin: ~50.2% in feces as parent and metabolites; metformin: <1% in bile).
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor/Biguanide Combination